Literature DB >> 11840353

The effect of angiotensin II on uveoscleral outflow in rabbits.

T Inoue1, T Yokoyoma, H Koike.   

Abstract

PURPOSE: In our previous study, we showed that the AT1 receptor antagonist increased uveoscleral outflow (USF) when topically applied to the rabbit eye. However this increase was too small to demonstrate a clear physiological role for ocular angiotensin II (AII). Hence, the purpose of this study was to determine whether ocular AII influenced USF regulation, and if so, how this occurred.
METHODS: USF was measured by the FITC-dextran perfusion method in albino rabbits. AII and its receptor antagonists were directly applied into the anterior chamber by adding into the perfusate and by perfusing with FITC-dextran. We also analyzed angiotensin receptors on the rabbit ciliary body membrane by a receptor binding assay with 125I-[Sar1), Ile8]-AII as a ligand.
RESULTS: CS-088 (1 microg/ml) increased USF by 24% while AII decreased USF in a concentration-dependent manner between 10 and 500 nM. Its maximum decrease of 19% occurred at 500 nM. At this AII concentration the USF reduction was antagonized by 1 microg/ml CS-088, an AT1-receptor antagonist, but not by the same concentration of PD-123,177, an AT2-receptor antagonist. Specific 125I-[Sar1, Ile8]-AII binding to the rabbit ciliary body membranes was inhibited by CS-088 with an inhibition constant of 7.05 nM, whereas inhibition by PD-123,177 was not observed.
CONCLUSIONS: Ocular AII was indicated to attenuate USF via AT1 receptors in rabbits, however its physiological effect was not critical in IOP regulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11840353     DOI: 10.1076/ceyr.23.2.139.5470

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  7 in total

1.  Advances in glaucoma treatment and management: outflow drugs.

Authors:  Paul L Kaufman; Carol A Rasmussen
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-04       Impact factor: 4.799

2.  Local ocular renin-angiotensin-aldosterone system: any connection with intraocular pressure? A comprehensive review.

Authors:  Mervi Holappa; Heikki Vapaatalo; Anu Vaajanen
Journal:  Ann Med       Date:  2020-04-30       Impact factor: 4.709

3.  Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats.

Authors:  Giselle Foureaux; Juçara Ribeiro Franca; José Carlos Nogueira; Gustavo de Oliveira Fulgêncio; Tatiana Gomes Ribeiro; Rachel Oliveira Castilho; Maria Irene Yoshida; Leonardo Lima Fuscaldi; Simone Odília Antunes Fernandes; Valbert Nascimento Cardoso; Sebastião Cronemberger; André Augusto Gomes Faraco; Anderson José Ferreira
Journal:  PLoS One       Date:  2015-07-23       Impact factor: 3.240

Review 4.  Therapeutic targets of renin-angiotensin system in ocular disorders.

Authors:  Rajesh Choudhary; Mandeep Singh Kapoor; Amrita Singh; Surendra H Bodakhe
Journal:  J Curr Ophthalmol       Date:  2016-10-20

5.  Continuous intraocular pressure monitoring in patients with obstructive sleep apnea syndrome using a contact lens sensor.

Authors:  Elena Carnero; Jean Bragard; Elena Urrestarazu; Estefanía Rivas; Vicente Polo; José Manuel Larrosa; Vanesa Antón; Antonio Peláez; Javier Moreno-Montañés
Journal:  PLoS One       Date:  2020-03-03       Impact factor: 3.240

6.  Association between chronic kidney disease and open-angle glaucoma in South Korea: a 12-year nationwide retrospective cohort study.

Authors:  Jun-Soo Ro; Jong Youn Moon; Tae Kwann Park; Si Hyung Lee
Journal:  Sci Rep       Date:  2022-03-01       Impact factor: 4.379

Review 7.  Many Faces of Renin-angiotensin System - Focus on Eye.

Authors:  Mervi Holappa; Heikki Vapaatalo; Anu Vaajanen
Journal:  Open Ophthalmol J       Date:  2017-06-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.